The lead compound MP1032 from Zurich company MetrioPharm could be a promising option for coronavirus treatment in future. The drug has demonstrated strong immunomodulatory and specific antiviral properties against SARS-CoV-2 in preclinical studies. It is currently being tested in a large-scale research project with three partner companies, namely Catalyze, MC Toxicology Consulting and ImmunoLogik.
The European Commission now intends to support this research project through funding under its HERA Incubator, as was reported in a press release. This funding program was launched in April 2021 to combat the coronavirus and its variants. MetrioPharm’s iMPact project is one of 11 initiatives selected for the program.
“We are very pleased with the announcement by the European Commission and the vote of confidence in our compound MP1032,” said MetrioPharm CEO Wolfgang Brysch in the press release. The decision is rated as support for the pharmaceutical development steps already taken and going forward for MP1032 in countering Covid-19.
Related news
Meet with an expansion expert
Is Greater Zurich on your expansion radar? We support you on every step of your expansion journey - from location evaluation to fact finding visits.
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Location evaluation support to find the ideal base for your business
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space
- And much more, customized to meet your needs.